Videos

​Darren Feldman, MD, assistant attending physician for the Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how to properly treat neutropenic fever as a toxicity stemming from chemotherapy treatment.

​Daniel Hamstra, MD, PhD, radiation oncologist, Texas Center for Proton Therapy, Texas Oncology, discusses the benefits of shorter radiotherapy treatment sessions for patients with prostate cancer.

Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the appropriateness of a more aggressive approach to men with high-risk prostate cancer. Cooperberg says currently, men will normally respond to surgery followed by adjuvant radiotherapy, as well as systemic therapy.

​Tomasz M. Beer, MD, FACP, deputy director, Knight Cancer Institute, Oregon Health and Science University, discusses the potential for genomic tests to result in new treatments.

Kenneth Wang, MD, director of the Advanced Endoscopy Group and Esophageal Neoplasia Clinic, Mayo Clinic, discusses his opposition for Barrett's esophagus screening as a preventative measure for esophageal adenocarcinoma.

Heimberger says the treatment paradigm's future is two-pronged, in that it will consist of both combination therapies that activate the immune system and prevent immunosuppression, as well as understand CT and MRI scans of brain cancer patients.

<div style="color:#003668"><em>"When there is a mismatch between the human genetics and bacterial genetics, this may be one of the factors that leads to gastrointestinal cancer."<p align="right"><span style="color:#747474">- Keith Wilson, MD</span></em></div></p>

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses identifying certain characteristics in a patient's brain tumor in order to administer better treatment.

Susan Panullo, MD, director, Neuro-oncology, director, Neurosurgical Radiosurgery, Weill Cornell Brain and Spine Center, discusses the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A).

Lorraine Pelosof, MD, PhD, assistant professor of Hematology and Oncology, UT Southwestern Medical Center, on the increasing proportion of non-smokers developing non-small cell lung cancer (NSCLC).

Eric Lim, MD, consultant thoracic surgeon, Royal Brompton Hospital, Senior lecturer in thoracic surgery and reader, Imperial College London, discusses the decline in smoking not correlating to the current amount of lung cancer diagnoses.

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the role genetic testing for colorectal cancer (CRC) plays in families.

&#8203;Charles M. Perou, PhD, professor of Genetics, Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses precision medicine in breast cancer and currently known biomarkers.

Geoffrey Shapiro, MD, PhD, director, Early Drug Development Center, Dana Farber, discusses the role of cyclin-dependent kinase (CDK4) in some breast cancer subtypes and the lack of targeted agents in triple-negative breast cancer.

Anthony Mato, MD, MSCE, director of the CLL Program, University of Pennsylvania, discusses the difference between intolerance and resistance when giving patients with chronic lymphotic leukemia ibrutinib.

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).

&#8203;John McCarty, MD, medical director, Bone Marrow Transplant Program, Virginia Commonwealth University Health, discusses advice physicians can give to patients with lymphoma seeking stem cell mobilization.

Aaron Logan, MD, PhD, discusses the evolving definition of immunotherapy and its importance within the realm of oncology. Logan says immunotherapies were initially meant try to vaccinate patients against their own tumors, though the methodologies involved did not prove successful.

&#8203;Michael A. Davies, MD, PhD, discusses the importance of identifying which patients diagnosed with melanoma are at the highest risk for developing brain metastases.

Ashani T. Weeraratna, PhD, discusses the similarities in treatment between younger and older patients with melanoma. She says this lack of differentiation between treatment regimens could pose a problem in the future. One such issue is that older patients tend to react less well to treatments like vemurafenib.

Sheri Holmen, PhD, discusses treating metastases in melanoma. Holmen says the treatment of metastases in melanoma is currently the cancer's biggest unmet clinical need, specifically brain metastases.

&#8203;Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non

Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.

Marianne Davies, NP, discusses making patients' oncology team their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether it is an immune-related side effect, or an issue that can be dealt with by their primary care physician.

Beer says that while BRCA is normally associated with breast cancer, the gene is found in up to 20% of advanced prostate cancers. He says of this 20% patient population, roughly half inherit the BRCA gene and the other half acquire it.

Srinivasan says enrolling patients in clinical trials that best represents their type of kidney cancer is an appropriate course of action for treatment.

Kutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.

Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC.

Plimack says the efficacy of PD-L1 inhibitors have been proven in the treatment of bladder cancer and are currently employed in the armamentarium of medical professionals. She adds as other cancer types further test both ipilimumab and PD-L1 inhibitors, oncologists will gain a better understanding of how both will continue to play a role in bladder cancer.